Related Experiment Video
Updated: Nov 5, 2025

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through
Raffaella Soldi1, Tithi Ghosh Halder1, Samuel Sampson1
1Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), Phoenix, Arizona (R.S., T.G.H., S.S., A.W., T.T., R.R.d.V., K.D., M.R.K., S.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.V.); MD Anderson Cancer Center, University of Texas, Department of Leukemia, Division of Cancer Medicine, Houston, Texas (K.N.B.); Iterion Therapeutics, Inc., Houston, Texas (S.K.H.); College of Medicine, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska (S.K.B.); City of Hope Comprehensive Cancer Center, Duarte, California (R.S.).
Abstract:
The central role of β-catenin in the Wnt pathway makes it an attractive therapeutic target for cancers driven by aberrant Wnt signaling. We recently developed a small-molecule inhibitor, BC-2059, that promotes apoptosis by disrupting the β-catenin/transducin β-like 1 (TBL1) complex through an unknown mechanism of action. In this study, we show that BC-2059 directly interacts with high affinity for TBL1 when in complex with β-catenin. We identified two amino acids in a hydrophobic pocket of TBL1 that are required for binding with β-catenin, and computational modeling predicted that BC-2059 interacts at the same hydrophobic pocket. Although this pocket in TBL1 is involved in binding with NCoR/SMRT complex members G Protein Pathway Suppressor 2 (GSP2) and SMRT and p65 NFκB subunit, BC-2059 failed to disrupt the interaction of TBL1 with either NCoR/SMRT or NFκB. Together, our results show that BC-2059 selectively targets TBL1/β-catenin protein complex, suggesting BC-2059 as a therapeutic for tumors with deregulated Wnt signaling pathway. SIGNIFICANCE STATEMENT: This study reports the mechanism of action of a novel Wnt pathway inhibitor, characterizing the selective disruption of the transducin β-like 1/β-catenin protein complex. As Wnt signaling is dysregulated across cancer types, this study suggests BC-2059 has the potential to benefit patients with tumors reliant on this pathway.
Insights
The Wnt signaling inhibitor BC-2059 targets the transducin beta-like 1 (TBL1)/beta-catenin complex. This selective disruption offers a potential therapeutic strategy for various cancers with deregulated Wnt pathways.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Signal Transduction
Background:
- Aberrant Wnt signaling drives cancer development, making beta-catenin a key therapeutic target.
- BC-2059 is a novel small-molecule inhibitor that induces apoptosis by disrupting the beta-catenin/transducin beta-like 1 (TBL1) complex.
- The precise mechanism of BC-2059 action remained previously uncharacterized.
Purpose of the Study:
- To elucidate the mechanism of action of the Wnt pathway inhibitor BC-2059.
- To characterize the interaction between BC-2059, TBL1, and beta-catenin.
- To determine the selectivity of BC-2059's inhibitory effects.
Main Methods:
- Biochemical assays to assess protein complex interactions.
- Site-directed mutagenesis to identify key amino acids in TBL1.
- Computational modeling to predict drug-target interactions.
- Assays to evaluate disruption of TBL1 interactions with other protein complexes.
Main Results:
- BC-2059 directly binds to TBL1 with high affinity within the beta-catenin complex.
- Two specific amino acids in a TBL1 hydrophobic pocket are crucial for beta-catenin binding.
- Computational modeling indicated BC-2059 targets this same hydrophobic pocket on TBL1.
- BC-2059 selectively disrupts the TBL1/beta-catenin interaction without affecting TBL1 interactions with NCoR/SMRT or NF-kappaB complexes.
Conclusions:
- BC-2059 selectively targets and disrupts the TBL1/beta-catenin protein complex.
- This targeted mechanism suggests BC-2059 as a promising therapeutic agent for cancers dependent on Wnt signaling.
- The findings provide a mechanistic basis for BC-2059's efficacy in Wnt-driven tumors.
Related Concept Videos
Canonical Wnt Signaling Pathway
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Non-Canonical Wnt Signaling Pathways
TGF - β Signaling Pathway
Inhibition of Cdk Activity
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

